This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rowe, T. C. Articles by Liu, L. F. Search for Related Content PubMed PubMed Citation Articles by Rowe, T. C. Articles by Liu, L. F.

DNA Damage by Antitumor Acridines Mediated by Mammalian DNA Topoisomerase II¹

Department of Biological Chemistry, Johns Hopkins Medical School, Baltimore, Maryland 21205

Antitumor drugs from many chemical classes have been shown to induce protein-linked DNA breaks in cultured mammalian cells and in vitro in the presence of purified mammalian DNA topoisomerase II. The possibility that mammalian DNA topoisomerase II is an intracellular target which mediates drug-induced DNA breaks is supported by the following studies using 4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA): (a) a single m-AMSA-dependent DNA cleavage activity copurified with calf thymus DNA topoisomerase II activity at all chromatographic steps of the enzyme purification; (b) m-AMSA-induced DNA cleavage by this purified activity resulted in the covalent attachment of protein to the 5'-ends of the DNA via a tyrosyl phosphate bond. This covalently linked protein has the same reduced molecular weight as purified calf thymus DNA topoisomerase II. The possibility that topoisomerase II-mediated DNA breaks may be responsible for cytotoxicity has also been investigated using a number of m-AMSA-related acridines. The level of topoisomerase II-mediated DNA breaks in vitro strongly correlates with the level of protein-linked DNA breaks in cultured cells and drug-induced cytotoxicity. These results suggest that mammalian DNA topoisomerase II may be a cytotoxic target of antitumor acridines.

¹ This work was supported by NIH Grants GM-27731 and CA-39662.

² American Cancer Society postdoctoral fellow. Present address: Department of Pharmacology and Therapeutics, University of Florida, Gainesville, FL 32610.

³ To whom requests for reprints should be addressed, at Department of Biological Chemistry, Johns Hopkins Medical School, 725 N. Wolfe St., Baltimore, MD 21205.

Received 9/ 9/85. Revised 1/ 7/86. Accepted 1/ 7/86.

This article has been cited by other articles:

				L. N. Harris, G. Broadwater, M. Abu-Khalaf, D. Cowan, A. D. Thor, D. Budman, C. T. Cirrincione, D. A. Berry, E. P. Winer, C. A. Hudis, et al. Topoisomerase II{alpha} Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013 J. Clin. Oncol., July 20, 2009; 27(21): 3430 - 3436. [Abstract] [Full Text] [PDF]

				A. Ganguly, B. Das, A. Roy, N. Sen, S. B. Dasgupta, S. Mukhopadhayay, and H. K. Majumder Betulinic Acid, a Catalytic Inhibitor of Topoisomerase I, Inhibits Reactive Oxygen Species Mediated Apoptotic Topoisomerase I DNA Cleavable Complex Formation in Prostate Cancer Cells but Does Not Affect the Process of Cell Death Cancer Res., December 15, 2007; 67(24): 11848 - 11858. [Abstract] [Full Text] [PDF]

				S. J. Wang, K. Peyrollier, and L. Y. Bourguignon The Influence of Hyaluronan-CD44 Interaction on Topoisomerase II Activity and Etoposide Cytotoxicity in Head and Neck Cancer Arch Otolaryngol Head Neck Surg, March 1, 2007; 133(3): 281 - 288. [Abstract] [Full Text] [PDF]

				S.-H. Juang, C.-C. Lung, P.-C. Hsu, K.-S. Hsu, Y.-C. Li, P.-C. Hong, H.-S. Shiah, C.-C. Kuo, C.-W. Huang, Y.-C. Wang, et al. D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation Mol. Cancer Ther., January 1, 2007; 6(1): 193 - 202. [Abstract] [Full Text] [PDF]

				C.-C. Kuo, J.-F. Liu, and J.-Y. Chang DNA Repair Enzyme, O6-Methylguanine DNA Methyltransferase, Modulates Cytotoxicity of Camptothecin-Derived Topoisomerase I Inhibitors J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 946 - 954. [Abstract] [Full Text] [PDF]

				J. E. Karp, A. Passaniti, I. Gojo, S. Kaufmann, K. Bible, T. S. Garimella, J. Greer, J. Briel, B. D. Smith, S. D. Gore, et al. Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-{beta}-D-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias Clin. Cancer Res., December 1, 2005; 11(23): 8403 - 8412. [Abstract] [Full Text] [PDF]

				J.-Y. Chang, J.-F. Liu, S.-H. Juang, T.-W. Liu, and L.-T. Chen Novel Mutation of Topoisomerase I in Rendering Cells Resistant to Camptothecin Cancer Res., July 1, 2002; 62(13): 3716 - 3721. [Abstract] [Full Text] [PDF]

				L. N. Harris, L. Yang, V. Liotcheva, S. Pauli, J. D. Iglehart, O. M. Colvin, and T. S. Hsieh Induction of Topoisomerase II Activity after ErbB2 Activation Is Associated with a Differential Response to Breast Cancer Chemotherapy Clin. Cancer Res., June 1, 2001; 7(6): 1497 - 1504. [Abstract] [Full Text] [PDF]

				P. S. Kingma and N. Osheroff Topoisomerase II-mediated DNA Cleavage and Religation in the Absence of Base Pairing. ABASIC LESIONS AS A TOOL TO DISSECT ENZYME MECHANISM J. Biol. Chem., July 17, 1998; 273(29): 17999 - 18002. [Abstract] [Full Text] [PDF]

				M. Olivier, B.-J. Romero-Gallo, C. Matte, J. Blanchette, B. I. Posner, M. J. Tremblay, and R. Faure Modulation of Interferon-gamma -induced Macrophage Activation by Phosphotyrosine Phosphatases Inhibition. EFFECT ON MURINE LEISHMANIASIS PROGRESSION J. Biol. Chem., May 29, 1998; 273(22): 13944 - 13949. [Abstract] [Full Text] [PDF]

				M. Binaschi, G. Capranico, L. Dal Bo, and F. Zunino Relationship between Lethal Effects and Topoisomerase II-Mediated Double-Stranded DNA Breaks Produced by Anthracyclines with Different Sequence Specificity Mol. Pharmacol., June 1, 1997; 51(6): 1053 - 1059. [Abstract] [Full Text]

				N. Fujii, Y. Yamashita, T. Mizukami, and H. Nakano Correlation between the Formation of Cleavable Complex with Topoisomerase I and Growth-Inhibitory Activity for Saintopin-Type Antibiotics Mol. Pharmacol., February 1, 1997; 51(2): 269 - 276. [Abstract] [Full Text] [PDF]